Trial register facet
Trial records in type 2 diabetes mellitus — page 3
247 records bearing on type 2 diabetes mellitus.
Showing 0 records on this page
Records
247 documents · page 3 of 11
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SURMOUNT-2 | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 938 | 2023 | High |
| RETA-PH2-T2D | Retatrutide | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 281 | 2023 | Moderate |
| ORFO-PH2-T2D | Orforglipron | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | 383 | 2023 | Moderate |
| CAGRI-SEMA-PH2-T2D | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, active-controlled | 92 | 2023 | Low |
| DANU-PH2B-T2D | Danuglipron | Phase 2b | Programme discontinued | Randomised, double-blind, placebo-controlled | 411 | 2023 | Not rated |
| SURMOUNT-2-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-HEPATIC-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| ORFO-PH2-T2D-HEPATIC-IMPprogramme record | Orforglipron | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-QOLprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-T2D-BODY-COMPprogramme record | Danuglipron | Phase 2b | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-2-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-DDIprogramme record | Retatrutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| ORFO-PH2-T2D-DDIprogramme record | Orforglipron | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-REGIONAL-CNprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-T2D-REGIONAL-JPprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-2-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-PKprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| ORFO-PH2-T2D-PKprogramme record | Orforglipron | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-REGIONAL-JPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| DANU-PH2B-T2D-REGIONAL-CNprogramme record | Danuglipron | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-2-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| RETA-PH2-T2D-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| CAGRI-SEMA-PH2-T2D-BODY-COMPprogramme record | CagriSema (cagrilintide with semaglutide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| RETA-PH2-T2D-REGIONAL-CNprogramme record | Retatrutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
page 3 of 11